{
    "nctId": "NCT04137653",
    "briefTitle": "Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT",
    "officialTitle": "Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1498,
    "primaryOutcomeMeasure": "Pathologic complete response (PCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* breast cancer is confirmed by the mammography, and the immunohistochemical results of cancer tissues are negative for estrogen receptor, progesterone receptor and anti-human epidermal growth factor receptor 2;\n* positive for axillary lymph node metastasis;\n* 18-70 years of age, female;\n* patients have good compliance with the planned treatment, who are volunteer to participate in the study, are willing to be treated with solvent-based paclitaxel or nab-P at random, and provide written informed consent with the premise of fully understanding the study protocol.\n\nExclusion Criteria:\n\n* pregnant and lactating women;\n* distant metastasis;\n* patients with a history of other cancers or who have received radiotherapy on the chest;\n* abnormalities in blood tests or presence of other symptoms of infection;\n* allergy to paclitaxel;\n* patients who have psychotropic drug abuse until now or those with a history of mental disorders;\n* abnormalities in important organs such as the heart, lung, liver and kidney;\n* patients who have participated in other clinical trials.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}